CA2309588A1 - Statin-matrix metalloproteinase inhibitor combinations - Google Patents
Statin-matrix metalloproteinase inhibitor combinations Download PDFInfo
- Publication number
- CA2309588A1 CA2309588A1 CA002309588A CA2309588A CA2309588A1 CA 2309588 A1 CA2309588 A1 CA 2309588A1 CA 002309588 A CA002309588 A CA 002309588A CA 2309588 A CA2309588 A CA 2309588A CA 2309588 A1 CA2309588 A1 CA 2309588A1
- Authority
- CA
- Canada
- Prior art keywords
- acid
- methyl
- phenyl
- ethyl
- oxo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7826598P | 1998-03-17 | 1998-03-17 | |
| US60/078,265 | 1998-03-17 | ||
| PCT/US1998/024681 WO1999047138A1 (en) | 1998-03-17 | 1998-11-20 | Statin-matrix metalloproteinase inhibitor combinations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2309588A1 true CA2309588A1 (en) | 1999-09-23 |
Family
ID=22142950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002309588A Abandoned CA2309588A1 (en) | 1998-03-17 | 1998-11-20 | Statin-matrix metalloproteinase inhibitor combinations |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1063991A1 (es) |
| JP (1) | JP2002506818A (es) |
| KR (1) | KR20010041916A (es) |
| AR (1) | AR018113A1 (es) |
| AU (1) | AU1591699A (es) |
| BR (1) | BR9815745A (es) |
| CA (1) | CA2309588A1 (es) |
| CO (1) | CO5070670A1 (es) |
| GT (1) | GT199900039A (es) |
| HN (1) | HN1999000029A (es) |
| MY (1) | MY140504A (es) |
| NZ (1) | NZ505994A (es) |
| PA (1) | PA8469001A1 (es) |
| PE (1) | PE20000348A1 (es) |
| SV (1) | SV1999000026A (es) |
| UY (1) | UY25436A1 (es) |
| WO (1) | WO1999047138A1 (es) |
| ZA (1) | ZA992106B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0100761D0 (en) | 2001-01-11 | 2001-02-21 | Biocompatibles Ltd | Drug delivery from stents |
| EP1827448A1 (en) | 2004-12-15 | 2007-09-05 | Solvay Pharmaceuticals GmbH | Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and hmg coa reductase inhibitors |
| KR101329112B1 (ko) * | 2005-11-08 | 2013-11-14 | 랜박시 래보러터리스 리미티드 | (3ｒ,5ｒ)-7-〔2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-〔(4-히드록시 메틸 페닐 아미노)카르보닐〕-피롤-1-일〕-3,5-디히드록시 헵탄산 헤미 칼슘염의 제조 방법 |
| US20110182851A1 (en) * | 2008-07-11 | 2011-07-28 | Jan Nilsson | Oxidized ldl specific antibody-fusion and conjugated proteins |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA000514B1 (ru) * | 1995-11-02 | 1999-10-28 | Варнер-Ламберт Компани | Способ нормализации липопротеидного профиля плазмы крови у млекопитающего и фармацевтическая композиция для его осуществления |
| EA001561B1 (ru) * | 1996-05-17 | 2001-04-23 | Варнер-Ламберт Компани | Бифенилсульфонамидные ингибиторы матричных металлопротеиназ |
| NZ334897A (en) * | 1996-12-09 | 2001-02-23 | Warner Lambert Co | Medicaments for treating and preventing heart failure and ventricular dilatation |
| TW536540B (en) * | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| GT199800126A (es) * | 1997-08-29 | 2000-01-29 | Terapia de combinacion. |
-
1998
- 1998-11-20 KR KR1020007010223A patent/KR20010041916A/ko not_active Application Discontinuation
- 1998-11-20 BR BR9815745-0A patent/BR9815745A/pt not_active Application Discontinuation
- 1998-11-20 CA CA002309588A patent/CA2309588A1/en not_active Abandoned
- 1998-11-20 JP JP2000536378A patent/JP2002506818A/ja active Pending
- 1998-11-20 AU AU15916/99A patent/AU1591699A/en not_active Abandoned
- 1998-11-20 NZ NZ505994A patent/NZ505994A/xx unknown
- 1998-11-20 WO PCT/US1998/024681 patent/WO1999047138A1/en not_active Application Discontinuation
- 1998-11-20 EP EP98960279A patent/EP1063991A1/en not_active Withdrawn
-
1999
- 1999-02-24 AR ARP990100751A patent/AR018113A1/es unknown
- 1999-03-15 MY MYPI99000951A patent/MY140504A/en unknown
- 1999-03-16 ZA ZA9902106A patent/ZA992106B/xx unknown
- 1999-03-16 UY UY25436A patent/UY25436A1/es not_active Application Discontinuation
- 1999-03-16 PA PA19998469001A patent/PA8469001A1/es unknown
- 1999-03-16 CO CO99016109A patent/CO5070670A1/es unknown
- 1999-03-16 GT GT199900039A patent/GT199900039A/es unknown
- 1999-03-16 PE PE1999000217A patent/PE20000348A1/es not_active Application Discontinuation
- 1999-03-16 SV SV1999000026A patent/SV1999000026A/es not_active Application Discontinuation
- 1999-03-16 HN HN1999000029A patent/HN1999000029A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PA8469001A1 (es) | 2002-09-17 |
| HN1999000029A (es) | 1999-09-29 |
| SV1999000026A (es) | 2000-01-18 |
| KR20010041916A (ko) | 2001-05-25 |
| ZA992106B (en) | 1999-09-30 |
| UY25436A1 (es) | 2001-10-25 |
| GT199900039A (es) | 2000-09-06 |
| WO1999047138A1 (en) | 1999-09-23 |
| PE20000348A1 (es) | 2000-05-22 |
| CO5070670A1 (es) | 2001-08-28 |
| AU1591699A (en) | 1999-10-11 |
| MY140504A (en) | 2009-12-31 |
| JP2002506818A (ja) | 2002-03-05 |
| AR018113A1 (es) | 2001-10-31 |
| NZ505994A (en) | 2003-10-31 |
| EP1063991A1 (en) | 2001-01-03 |
| BR9815745A (pt) | 2000-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU741768B2 (en) | Method for treating and preventing heart failure and ventricular dilatation | |
| AU751701B2 (en) | Ace inhibitor-MMP inhibitor combinations | |
| US6340709B1 (en) | Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing | |
| CA2335062A1 (en) | Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions | |
| US20020049237A1 (en) | Statin-MMP inhibitor combinations | |
| CA2309588A1 (en) | Statin-matrix metalloproteinase inhibitor combinations | |
| US20050020607A1 (en) | Statin-MMP inhibitor combinations | |
| AU2003248291A1 (en) | Statin-matrix metalloproteinase inhibitor combinations | |
| MXPA00005034A (es) | Combinaciones de statin-inhibidores de la matriz de la metaloproteinasa | |
| MXPA00003736A (es) | Combinaciones de inhibidor ace-inhibidor mmp | |
| EP1366765A1 (en) | Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing | |
| MXPA01000780A (es) | Coadministracion de inhibidores acat y mmp para el tratamiento de lesiones arteroescleroticas | |
| MXPA99002254A (es) | Uso de inhibidores de metaloproteinasa matriz para tratar desordenes neurologicos y promover la curacion de heridas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |